Outcomes Research

 
Stock Quotes for Outcomes Research top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
Sign-up for cot investment picks

 
News Articles for Outcomes Research top ^
2013/11/6
iGATE Secures Largest Outcomes-Based Contract with UBS for a Managed Data Service Powered by Markit Enterprise Data Management Canada NewsWire In a significant multi-year contract,   iGATE - powered by Markit Enterprise Data Management - will provide financial instrument data services globally for the global financial services firm LONDON , ISELIN, NJ and BANGALORE, India , Nov.
Sign-up for iGATE Secures Largest Outcomes-Based Contract with UBS for a Managed Data Service Powered by Markit Enterprise Data Management investment picks
LONDON , ISELIN, New Jersey and BANGALORE, India , November 6, 2013 /PRNewswire/ -- In a significant multi-year contract ,   iGATE - powered by Markit Enterprise Data Management - will provide financial instrument data services globally for the global financial services firm iGATE Corporation (NASDAQ: IGTE) , the first Integrated Technology and Operations (iTOPS) company providing Business Outcomes-based solutions, announced today that it has secured a major contract with global financial services firm UBS AG (UBSN: SIX Swiss Ex).      (Logo: http://photos.prnewswire.com/prnh/20130717/629294 ) UBS currently has a landscape with multiple technology systems and operations across multiple vendors supporting instrument reference data management.
Sign-up for iGATE Secures Largest Outcomes-Based Contract with UBS for a Managed Data Service Powered by Markit Enterprise Data Management investment picks
2013/8/13
Certification ensures Waypoint can be efficiently adopted into all Learning Management Systems certified by the IMS Global Learning Consortium SAN DIEGO , Aug.
Sign-up for Waypoint Outcomes Achieves Certification for Learning Tools Interoperability v1.1 investment picks
2014/2/27
Infosys BPO Creates the Process Progression Model™ to Improve Business Outcomes for Clients Canada NewsWire BANGALORE, India , Feb.
Sign-up for Infosys BPO Creates the Process Progression Model™ to Improve Business Outcomes for Clients investment picks
2013/9/9
Virtusa Corporation   (NASDAQ: VRTU) , a global IT services company that combines innovation, technology leadership and industry solutions to transform the customer experience, is working closely with Pegasystems (NASDAQ: PEGA) on implementations of its Product Composer System (PCS) framework, an agile solution designed to help healthcare companies rapidly and successfully develop and manage innovative healthcare products.
Sign-up for Virtusa Partners with Pegasystems to Help Healthcare Organizations Accelerate Business Outcomes with Pega Product Composer System (PCS) investment picks
2014/2/27
Baxter International Inc. (NYSE:BAX) today presented clinical data on Baxter’s leading recombinant factor VIII treatment, including interim data from the first year of observation from the AHEAD (ADVATE HaEmophilia A Database) study, a four-year outcomes registry of hemophilia A patients treated with ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method]. These data were presented during the European Association for Haemophilia and Allied Disorders (EAHAD) meeting in Brussels, Belgium.
Sign-up for Baxter Presents Data at EAHAD from Long-Term Outcomes Registry Reinforcing Prophylaxis Treatment Experience with ADVATE investment picks
2013/9/26
Improvements in several indicators of diabetes management, including perceptions about hyperglycaemia and weight, observed for investigational GLP-1 receptor agonist BARCELONA, Spain , Sept.
Sign-up for Data Presented at 49th EASD Annual Meeting Show Treatment with Lilly's Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes investment picks
In support of the more than 1.1 million people living with HIV in the U.S., Walgreens (NYSE: WAG) (Nasdaq: WAG) is collaborating with the Centers for Disease Control and Prevention (CDC) to develop and evaluate a model of HIV patient-centered care through a national project aimed at advancing clinical integration and medication therapy management.
Sign-up for Walgreens Announces Collaboration with Centers for Disease Control and Prevention to Improve HIV Prevention and Outcomes investment picks
2013/8/29
Companies embark on evidence-based research effort to advance health care outcomes LOUISVILLE, Ky.
Sign-up for Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes investment picks
2013/9/26
AstraZeneca (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced additional results from the SAVOR cardiovascular outcomes trial, which found no increased rate of hypoglycemia among patients treated with Onglyza ® (saxagliptin) compared to placebo when added to metformin monotherapy and higher rates of hypoglycemia only in the Onglyza group compared to the placebo group among patients taking sulfonylureas, agents known to cause hypoglycemia, at baseline.
Sign-up for New Hypoglycemia and Pancreatitis Subanalyses from the Onglyza® (saxagliptin) SAVOR Cardiovascular Outcomes Trial Presented at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) investment picks
2013/11/18
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ ® (tofacitinib citrate) to include additional Patient-Reported Outcomes (PRO) data in the label.
Sign-up for Pfizer Announces FDA Approval of Supplemental Application to Expand XELJANZ® (tofacitinib citrate) Labeling to Include Additional Patient-Reported Outcomes Data for Adults with Moderately to Severely Active Rheumatoid Arthritis investment picks
2013/11/26
Chorus Aviation Inc. confirms successful outcome of benchmarking arbitration with Air Canada Canada NewsWire Ruling Upholds Current 12.5% Controllable Mark-Up Board Continues to Review Opportunities to Further Enhance Shareholder Value HALIFAX , Nov.
Sign-up for Chorus Aviation Inc. confirms successful outcome of benchmarking arbitration with Air Canada investment picks
2013/9/3
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited (Takeda) announced top line results of the EXAMINE ( EX amination of C A rdiovascular Outco M es: Aloglipt IN vs.
Sign-up for Furiex Confirms Alogliptin Cardiovascular Safety Outcomes Trial (EXAMINE) Met Primary Endpoint investment picks
2013/9/2
AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) today announced the full results of the SAVOR clinical trial in 16,492 adult patients with type 2 diabetes at high risk for cardiovascular events.
Sign-up for Onglyza® (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death, Heart Attack or Stroke in SAVOR Cardiovascular Outcomes Trial investment picks
2013/11/22
http://media.marketwire.com/attachments/201311/68896_acutronic.jpg http://media.marketwire.com/attachments/201307/63356_Masimo_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1071071&ProfileId=051205&sourceType=1 ZURICH, SWITZERLAND and IRVINE, CA --
Sign-up for ACUTRONIC Medical Systems Integrates Masimo SET(R) Pulse Oximetry Into fabian HFO Neonatal Critical Care Ventilators for Improved Patient Outcomes investment picks
Torrance Memorial Selects Halogen Software to Improve Patient Outcomes by Supporting Employee Development Canada NewsWire Top California hospital looks to build strong performance and development foundation with Halogen's award winning suite for healthcare OTTAWA , Dec.
Sign-up for Torrance Memorial Selects Halogen Software to Improve Patient Outcomes by Supporting Employee Development investment picks
2014/2/24
Significant Advancement in the Classification and Prediction of Kidney Cancer Outcomes Validated in Collaborative 191 Patient Clinical Study with Cleveland Clinic Using CGI's Genomic Microarray Test RUTHERFORD, N.J., Feb.
Sign-up for Cancer Genetics, Inc. Announces a New Breakthrough for Diagnosis and Prediction of Kidney Cancer Outcomes Using Its Proprietary Genomic Test investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Outcomes Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Other World  |  Next: Outlook Survey